探索缩性微质细胞与阿尔茨海默氏症神经病理学的传播之间的联系
Ryan K Shahidehpour1,2,3, Peter T Nelson2,3,4, Yuriko Katsumata2,5
1Spinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY 40536, USA.
Brain : a journal of neurology
|August 5, 2024
概括
与衰老相关的亚型 - - 衰变性微质细胞在阿尔茨海默氏症 (AD) 脑区显著增加. 陶氏病理启动了它们的发展,可能通过影响粉样β和陶氏传播来推动AD的进展.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 微质在阿尔茨海默病 (AD) 中至关重要,但它们的疾病驱动机制尚不清楚.
- 缺陷性微质,以碎片化过程为特征,与衰老和神经退行有关.
- 粉样蛋白-β和病理可能会诱导微质缩,将蛋白质病变与微质变化联系起来.
研究的目的:
- 研究缩性微质在阿尔茨海默病进展中的作用.
- 为了确定与其他蛋白质病变相比,缩性微质细胞是否特异于AD神经病理学.
- 探索缩性微质细胞和AD病理的传播之间的关系.
主要方法:
- 分析了来自6个疾病状态的64个个体的人类大脑部分.
- 立体采样和数字病理学,以量化微质子类型 (分支,过度缩,缩).
- 调解分析和结构方程建模,以评估病理和微细胞之间的关系.
主要成果:
- 在早期AD受影响的大脑区域观察到缩性微质细胞的显著增加.
- 与其他神经退行性疾病相比,在阿尔茨海默氏症中,缩性微质细胞的数量显著增加.
- 调解分析表明tau启动了缩性微质细胞的发展,然后与粉样蛋白-β和tau传播相关联.
结论:
- 消耗性微质细胞在阿尔茨海默氏症神经病理学中起着疾病特异性的作用.
- 保护性微质功能的丧失可能会导致AD的进展.
- 对于阿尔茨海默病的治疗策略,需要进一步研究保护微质功能.
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Amyloid Fibrils
9.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.4K


